Platelets play a major role in the initiation of thrombus formation and this is particularly true of thrombi arising on the arterial side of the circulation (Mustard and Packham, 1970a) . Platelet function may be studied in a number of systems in vitro and the effect of various drugs thereby assessed. The pyrimidopyrimidine derivatives have been widely studied in this respect but many other compounds interfering with platelet action have been described and the subject has recently been reviewed by Mustard and Packham (1970b) . The early pyrimido-pyrimidine derivative dipyridamole (RA8, Persantin, Boehringer Ingelbeim, Limited) was found to be effective in vitro in inhibiting platelet aggregation induced by ADP (Emmons, Harrison, Honour, and Mitcbell, 1965a; Gray, Wilson, and Douglas, 1968) , platelet aggregation in the Chandler tube system, and platelet adhesiveness (Gray et al, 1968) . Dipyridamole has also been demonstrated to inhibit thrombus forming at sites of vascular injury in experimental animals (Emmons, Harrison, Honour, and Mitchell, 1965b; Didisheim, 1968) , and in a controlled trial with random allocation has been shown to be of value when combined with oral anticoagulants in reducing the incidence of embolic episodes in patients with prosthetic heart valves as compared with patients on anticoagulants alone (Sullivan, Harken, and Gorlin, 1969) . Since the introduction of dipyridamole, other pyrimido-pyrimidine derivatives have been developed and found in certain in-vitro systems to inhibit Received for publication 19 October 1971. platelet function more powerfully. RA 433 was found to be a more potent inhibitor of ADP-induced platelet aggregation in vitro than dipyridamole (Elkeles, Hampton, Honour, Mitchell, and Prichard, 1968; Forbes, McNicol, and Douglas, 1969) but had no effect on thrombus formation in the experimental animal (Elkeles et al, 1968) . RA 233 in turn, in a direct comparison with RA 433, has been found to be the more powerful inhibitor of ADP-induced platelet aggregation, of platelet aggregation induced by calcium in a turbidimetric system, and of platelet adhesiveness (Hassanein, Turpie, McNicol, and Douglas, 1970) . This study deals with the effect uponhumanplatelet function in vitro of two new compounds, VK 774 and VK 744, chemically distinct from but historically related to pyrimido-pyrimidine derivatives. Their activity in this respect is directly compared with the pyrimido-pyrimidine derivative RA 233.
Chemistry
VK 774 is 4-morpholino-2-piperazino-thieno-(3, 2-D) pyrimidine-dihydrochloride, and VK 744 is 2-((2 aminoethyl)amino)-4-morpholinothieno (3, 2-D) Citrated blood was collected by clean venepuncture in plastic syringes with 21-gauge needles, 9 volumes of blood being mixed with 1 volume of 3-8% trisodium citrate in siliconized graduated centrifuge tubes maintained at room temperature. Platelet-rich plasma was obtained by centrifugation of citrated whole blood at 600 g for five minutes at room temperature. Siliconized glassware was used throughout (Siliclad, Clay-Adams, Inc, New Jersey).
Methods
The following parameters of platelet function were studied and the methods are described in detail by Forbes et al (1969) .
ADP-INDUCED PLATELET AGGREGATION
This was studied by the method of Born (1962) at room temperature. Platelet-rich plasma (1 -8 ml) was incubated at room temperature for five minutes with 0-2 ml dilutions of test solution or with solvent control, and challenged by 0 5 ,tg of ADP (final concentration 0-24 ,ug ADP/ml solution). The optical density was recorded every 10 seconds for 10 minutes after addition of ADP.
Indices of platelet aggregation and disaggregation are expressed as follows: 30-60 platelet aggregation is fall in optical density between 30 and 60 seconds after the addition of ADP; maximum aggregation is the difference between the lowest recorded optical density and the constant arbitrary baseline of0-600; percentage disaggregation is the ratio between the increment in optical density occurring in five minutes from the point of maximum aggregation and the maximum platelet aggregation.
PLATELET ADHESIVENESS
The glass bead column technique of Hellem (1960) as modified by Hirsh, McBride. and Dacie (1966) was used. Citrated whole blood (4-0 ml) was incubated at room temperature for 10 minutes with 0-04 ml of test solution or control.
RELEASE OF PLATELET FACTOR 3 BY KAOLIN
A modification of the technique of Spaet and Cintron (1965) was used. Platelet-rich plasma (0-9 ml) was preincubated at 37°C for 10 minutes with test dilutions or solvent control (0-1 ml).
CHANDLER TUBE TECHNIQUE
The method used was that described by Chandler (1958) as modified by Cunningham, McNicol, and Douglas (1965) . Small volumes were usec rich plasma (10 ml), 0-877% saline (28 test solution or solvent control (0 04 incubated in the Chandler tube at 3704 minutes before recalcification with 0-25s chloride (01 ml).
WHOLE BLOOD CLOT RETRACTION
A modification of the method described and Lewis (1968) was used; whole blood was mixed in siliconized centrifuge tubes copper wire spirals with test solution control (0-05 ml) before clot formation. 1: platelet-,6 ml), and ml) were C for five M calcium
Platelet counts were performed with formal-citrate as the diluting fluid (Dacie and Lewis, 1968 (p < 0-001).
In seven experiments at a concentration *CONTROLS of 10-6M, of the three drugs, only VK 774 had a statistically significant effect in the system, producing inhibition of 30 to 60 sec aggregation (0 01 > p > 0 001) and of maximum platelet aggregation (p < 0-001). Figure 1 shows the mean results of the three drugs in the 14 experiments at 10-5M concentration, and of the effect of VK 774 at 10-fM concentration compared with solvent controls. tion in platelet factor 3 release. VK 774 was more potent in this respect than VK 744 (p = 0001), which in turn was more powerful than RA 233 (0 01 > p > 0-001). At a concentration of 10-M in seven experiments only VK 774 had a statistically significant effect (p < 0-001). These results are shown in Figure 3 .
CHANDLER TUBE TECHNIQUE
The results obtained in seven experiments using VK 774, VK 744, and RA 233 at a final concentration of 10-4M compared with solvent controls are shown in Figure 4 . VK 774 and RA 233 produced significant prolongation of platelet aggregation time ('snowstorm' effect). They also considerably reduced the magnitude of the snowstorm effect as judged by inspection; this action was particularly noticeable with VK 774. VK 744 had no significant effect in this system.
WHOLE BLOOD CLOT RETRACTION
In seven experiments at 10-4M concentration VK 774, VK 744, and RA 233 had no statistically significant effect on percentage clot retraction although some of the clots with VK 774 were noted to be friable and soft. 
Discussion
The first step in the initiation of thrombus formation is the adherence and aggregation of platelets to each other and to the vessel wall (Mustard, Murphy, Rowsell, and Downie, 1962) , and ADP released into the blood stream by various mechanisms appears to play a major part in stimulating this process (Mustard and Packham, 1970a) . Subsequent release of platelet factor 3 (phospholipoprotein), promoted by platelet aggregation (Mustard, Hegardt, Rowsell, and MacMillan, 1964; Hardisty and Hutton, 1966) , accelerates the clotting mechanism and leads to stabilization of the thrombus with fibrin production, and eventual clot retraction reduces the friability of the clot. Substances capable of inhibiting platelet adhesion and aggregation, release of platelet factor 3, and clot retraction, may be expected to be of possible therapeutic value. Which particular platelet function test best reflects the thrombus-forming properties of a platelet is. however, unknown, and tests in vivo using the injured artery model are not necessarily more valid than tests in vitro (Elkeles et al, 1968) . A useful review of platelet function tests and their relevance to thrombosis has been given by Hampton (1967) .
The place of anticoagulant therapy in arterial thrombosis remains controversial. Platelet behaviour, of central importance in the initiation of thrombi, especially arterial, is largely uninfluenced by anticoagulant drugs. Drugs such as the pyrimidopyrimidine derivatives which interfere with platelet function, however, offer a potential therapeutic advance in the management of arterial thrombosis, and there is already clinical and experimental evidence of the usefulness of dipyridamole in the prevention of thromboembolic complications of prosthetic heart valves (Sullivan et al, 1969; Harker and Slichter, 1970) . So far neither RA 433 nor RA 233 have been evaluated clinically though they are well absorbed orally and appear to be relatively nontoxic in experimental animals (Elkeles et al, 1968; Hassanein et al, 1970) . VK 774 and VK 744 are two new compounds developed from the pyrimidopyrimidines and their effect on platelet function in vitro is reported and compared directly with that of RA 233. VK 774 and VK 744 inbibit ADP-induced platelet aggregation and VK 774 is considerably more powerful in this respect, almost completely inhibiting aggregation at 10-5M and being the only drug still significantly effective at 10-6M. VK 744, and to a significantly lesser degree RA 233, increase platelet disaggregation though there is no significant effect on aggregation by RA 233 at the concentrations used. Platelet adhesiveness is significantly reduced only by VK 774, VK 744, and RA 233 having no significant effect at the concentration used.
All three drugs impair the release of platelet factor 3 by kaolin, the VK compounds proving more potent in this respect than RA 233, and VK 774 having statistically the most powerful effect. At a concentration of 10-6M again only VK 774 has a statistically significant inhibitory effect on platelet factor 3 release. Platelet aggregation in the Chandler tube system, as estimated by the time of appearance of the snowstorm effect of aggregation, is significantly inhibited by VK 774 and RA 233 but not by VK 744. There is no significant difference noted between VK 774 and RA 233. They both also considerably reduce the magnitude of the snowstorm effect and this is particularly noticeable with VK 774 witb which clotting occurs with little or no recognizable prior snowstorm effect of platelet aggregation. In the concentration used there is no effect on percentage whole blood clot retraction by any of the three drugs although the final clot with VK 774 is noted in some cases to be friable and soft.
These results show that VK 774 and VK 744 have anti-platelet properties similar to the previously tested pyrimido-pyrimidine derivatives RA 233, RA 433, and dipyridamole, and in some of the invitro systems tested are significantly more powerful.
Of the two VK compounds tested, VK 774 stands out clearly in this study to be considerably the more potent drug and therefore the most powerful of these compounds so far reported. Initial toxicity studies with VK 774 are promising, and if these are satisfactorily completed it should be an important agent for therapeutic trial. 
